DHR vs INTC: Which Is the Better Buy?
Side-by-side comparison of Danaher Corporation and Intel Corp. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-15.
Danaher Corporation · Healthcare
$195.98
+7.9% upside to fair value
Grade B
High Quality
VS
Intel Corp. · Technology
$107.76
-5.2% upside to fair value
Grade D
QuantHub Verdict
DHR has more upside to fair value
(+7.9%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
DHR |
INTC |
| Current Price |
$195.98 |
$107.76 |
| Fair Value Estimate |
$211.54 |
$102.16 |
| Upside to Fair Value |
+7.9%
|
-5.2%
|
| Market Cap |
$138.7B |
$541.6B |
| Forward P/E |
37.8x
|
-173.8x
|
| EV / EBITDA |
22.8x
|
49.9x
|
| Price / Sales |
5.6x
|
10.1x
|
| Price / FCF |
26.2x
|
-173.7x
|
| Revenue Growth YoY |
+3.7%
|
+7.2%
|
| Gross Margin |
60.7%
|
35.4%
|
| Operating Margin |
21.0%
|
-9.4%
|
| Return on Equity |
7.1%
|
-3.0%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
3.81%
|
—
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
Danaher Corporation operates in the healthcare sector, specifically in medical diagnostics and research, delivering high-quality products with a durable competitive moat supported by strong margins and consistent earnings growth. The company trades at a trailing and forward P/E of 37.76, which is relatively high but justified by its stable revenue growth of 3.7% and earnings growth of 7.9% in the…
Intel Corporation is a leading semiconductor company operating in the technology sector, specializing in designing and manufacturing microprocessors and related technologies. The business quality is currently low due to negative earnings growth of 354.1% in the most recent quarter and negative profitability metrics including a net margin of -5.9% and an operating margin of -9.4%. Despite a revenu…
Accumulation Zones
| Metric |
DHR |
INTC |
| Zone Low |
$158.66 |
$76.62 |
| Zone High |
$179.81 |
$86.84 |
| In Buy Zone? |
No
|
No
|